Alchemy to be part of Integrated; taps Klein from KPR

Share this article:
Interpublic Group has assigned consumer agency Alchemy to operate under the purview of Integrated Communications. Stu Klein, formerly president and CEO of KPR, has been hired as Alchemy EVP, general manager. The restructuring and hiring were announced today by Steve Viviano, president of Integrated. Alchemy, which handles consumer creative for prescription and OTC accounts, such as Johnson & Johnson’s Pepcid, Mylanta, Motrin and Imodium, had operated autonomously since spinning off from consumer shop Lowe in 2002. It now joins Lowe Healthcare for the first time. Moving Alchemy to Integrated caps a five-year-old relationship between the two agencies. The IPG sibs worked side by side on consumer and professional ads for Ortho McNeil brands such as Ortho Tri-Cyclen Lo, Ortho Evra and Ditropan XL. Rather than continue to partner as sister agencies, IPG decided Alchemy should join Integrated. New York-based Alchemy also provides additional space for the fast-growing Integrated, which is based in New Jersey. Lowe Healthcare network was formed in 1997 and includes the creative agencies Integrated Communications, Interlink Healthcare Communications, Pace and Trio Communications.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...